Tag

CORONA Remedies Limited

7 articles

Corona Remedies Limited demonstrated robust financial performance in fiscal year 2026, with revenue increasing by 17.3% to INR 1,403 crore and profit after tax surging 33.4% to INR 199.4 crore. The company’s growth was fueled by strategic acquisitions, including Wokadine® from Dr. Reddy’s and several brands from Bayer Zydus, expanding its presence in key therapeutic areas like Povidone Iodine and infertility. Management anticipates continued momentum, projecting 15%+ organic revenue growth and 20%+ PAT growth for fiscal 2027, underpinned by new divisions and expansion into Eurasian markets, suggesting a positive outlook for investors seeking exposure to India’s pharmaceutical sector.

Company News

Corona Remedies Attends May Investor Conferences

Corona Remedies intimates participation in two investor conferences hosted by Ambit Capital and 360 ONE Capital in Mumbai on May 26-27, 2026. Company officials will attend group and one-on-one meeting

Results

Corona Remedies Q4FY26 PAT Surges 44% YoY

Corona Remedies held its Q4FY26 earnings call, reporting a 20.2% YoY revenue growth to INR 353 crore and a 44% YoY PAT surge to INR 45 crore. Full-year FY26 revenue grew 17.3% to INR 1,403 crore with

Results

Corona Remedies Q4 FY26 Earnings Call Audio Available

Corona Remedies intimated exchanges that audio recording of its Q4 FY26 earnings call with analysts is now available on company website. The conference call discussed audited financial results for fou

Results

CORONA Remedies Q4 FY26 Revenue Up 20.2% YoY

CORONA Remedies reported Q4 FY26 revenue growth of 20.2% YoY to ₹353.1 Cr and FY26 growth of 17.3% to ₹1,403.2 Cr. The company acquired Wokadine® from Dr. Reddy's and 7 brands from Bayer Zydus, expand